Skip to main content
. 2014 Jun 27;9(6):e101209. doi: 10.1371/journal.pone.0101209

Figure 5. Losartan displays characteristics of competitive antagonists.

Figure 5

Platelet aggregation responses to the GPVI-specific agonist CRP-XL were determined to a range of concentrations in the presence or absence of 30 µM drug. Losartan (a) significantly reduced the EC50 of CRP (F(1,58) = 15.79, p = <0.001). Cinanserin (b) also reduced the EC50 of CRP (F(1,60) = 4.07, p = 0.048).